



## **Thanks to an agreement signed with the Neocodex genomic research company**

### **CORPORACIÓN DERMOESTÉTICA WILL CARRY OUT GENETIC STUDIES TO PREVENT OBESITY**

**This collaboration will determine the genetic markers responsible for obesity among the Spanish population.**

**Valencia, XX September 2007.- Corporación Dermoestética has signed an agreement with Neocodex to offer clients of this medical aesthetic company a DNA study to determine their predisposition to suffer from obesity or any other pathologies associated with overweight. Neocodex is a recognised genomics research company which uses biomedicine to develop new diagnostic methods applicable to human health.**

The increasing concern for providing effective solutions to problems resulting from overweight has led Corporación Dermoestética to offer its clients the possibility of discovering in advance their genetic tendency to suffer from such problems. **As a result, doctors from Corporación Dermoestética will be able to offer the patient better solutions to obesity based on this information.**

#### **Genetic origins of diseases**

Genetic studies applied to aesthetics offer a wide range of effective solutions, even more so given that, according to experts, there are almost 10,000 diseases that are known to be inherited as a result of dominant patterns of inheritance. **With this agreement, the clients of Corporación Dermoestética would be able to discover, for example, their predisposition to suffer from alopecia in the future, their skin ageing levels or the risks of developing heart problems, breast cancer or Alzheimer's disease, etc.**

The genetic studies, which will be carried out by means of saliva, will be available to clients of Corporación Dermoestética in the next few months and may be contracted independently or as a supplement to treatments for obesity.

#### **Study of genetic markers responsible for obesity**

Neocodex is a leading genomics research company within the biomedical field. Their objective is to discover the genetic and molecular bases of common diseases in humans. The company currently has the largest Biobank in Spain with more than 15,000 samples, which enables them to perform, among many other aspects, studies on large series of the population with cardiovascular risk. These studies are used to determine which genetic factors are most relevant to the populations being studied.

This therefore facilitates scientific research within the field of human health, designing solutions which are adapted to the genetic profile of the population group being studied.



**With this collaboration, Neocodex will verify for the Spanish population the genetic markers which determine whether obesity may be developed in the patients studied.**

#### **Improved patient services**

On the other hand, Corporación Dermoestética has been working for the image and health of its clients for more than 27 years. It is currently present in Spain, Italy, Portugal and the United Kingdom, where it offers the most advanced medical and aesthetic services in Europe. The company directors state that **this agreement, which is included in the 2007-2011 Strategic Plan, forms part of the Corporación Dermoestética's concern to offer its clients the most advanced techniques and the latest technologies related to health and beauty.** They have also shown their absolute confidence in the benefits obtained from genetics, a field which has progressed extraordinarily in recent years and which offers exceptional potential for development.